Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety
- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.
Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an
Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in
In addition to chondrosarcoma,
The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.
The market responded strongly to the announcement, with
Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to
INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dogecoin News Today: Dogecoin's Foray into Football Seeks to Drive Practical Use Despite Ongoing Price Challenges
- Dogecoin (DOGE) faces bearish pressure near $0.20 resistance, with sellers dominating amid failed breakouts and macroeconomic headwinds. - Technical indicators signal oversold conditions, while $0.194–$0.196 support zone could trigger rebounds or deeper corrections. - House of Doge's acquisition of Italian football club Triestina aims to boost real-world adoption via DOGE payments for tickets and merchandise. - Market remains divided: $0.20 retest could reignite bullish momentum, while breakdown below $0

Solana Updates: Digital Asset Tokenization and AI-Driven DeFi—How Blockchain Is Shaping the Next Era of Finance
- Blockchain accelerates finance convergence as DeFi, tokenized assets, and AI-driven protocols redefine liquidity and accessibility. - NetBrands appoints DeFi expert Zachary Smith to bridge Bitcoin mining with on-chain liquidity, while Robinhood tokenizes 493+ assets on Arbitrum. - USD.AI monetizes idle crypto liquidity for AI data centers (13-17% yields), and Fidelity adds Solana to expand institutional DeFi access. - Aave-Maple collaboration integrates real-world assets into DeFi lending, while regulato

Instagram has introduced a new option that allows you to revisit Reels you have previously viewed
How to utilize the latest ChatGPT app integrations, such as Spotify, Figma, Canva, and more
